Novel approaches in the therapy of metastatic renal cell carcinoma.
about
Axitinib for the management of metastatic renal cell carcinomaTherapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinomaDifferential expression of prognostic proteomic markers in primary tumour, venous tumour thrombus and metastatic renal cell cancer tissue and correlation with patient outcomeLinkage of microRNA and proteome-based profiling data sets: a perspective for the priorization of candidate biomarkers in renal cell carcinoma?Incidence and mortality of kidney cancers, and human development index in Asia; a matter of concernSunitinib malate for the treatment of solid tumours: a review of current clinical data.Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors.Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma.GOLPH3 is a novel marker of poor prognosis and a potential therapeutic target in human renal cell carcinoma.Metastatic Renal Cell Carcinoma to Jejunum: An Unusual Case Presentation.Downregulation of the tumor suppressor HSPB7, involved in the p53 pathway, in renal cell carcinoma by hypermethylation.Can Initial (18)F-FDG PET-CT Imaging Give Information on Metastasis in Patients with Primary Renal Cell Carcinoma?Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach.Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma.Efficacy and safety of sunitinib on metastatic renal cell carcinoma: a single-institution experience.Clinical potential of TCF21 methylation in the diagnosis of renal cell carcinomaExpression of drug targets in primary and matched metastatic renal cell carcinoma tumors.Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib.Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational StudiesSimvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway.Severe Dyspnea due to Pulmonary Metastasis of Renal Cell Carcinoma: Is Cytoreductive Surgery of Value?Targeting the tumor microenvironment: focus on angiogenesis.Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examinationAre all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines.Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer.Cytoplasmic Accumulation of Heterogeneous Nuclear Ribonucleoprotein K Strongly Promotes Tumor Invasion in Renal Cell Carcinoma Cells.ABCG2 is a potential prognostic marker of overall survival in patients with clear cell renal cell carcinoma.The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinomaConcomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer.Cytoreductive nephrectomy in metastatic renal cell carcinoma.VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.Chrysophanic Acid Induces Necrosis but not Necroptosis in Human Renal Cell Carcinoma Caki-2 Cells.Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST).An integrative and comparative study of pan-cancer transcriptomes reveals distinct cancer common and specific signatures.Prognostic markers and targeted therapies for renal cell carcinoma.Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinibManaging metastatic renal cell carcinoma-challenges, pitfalls, and outcomes in the real worldA phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.Polypyrimidine Tract-Binding Protein 1 promotes proliferation, migration and invasion in clear-cell renal cell carcinoma by regulating alternative splicing of PKM
P2860
Q24613720-5BF9B8B2-63C0-49BA-A35B-75409ABBC6AFQ27013665-AABB3882-6292-495B-A664-61B1E9AFD378Q28486028-B398A3B8-E2AF-4E93-9577-C91540EA951EQ30318519-89376DA8-372B-488D-A1B9-3D6ACEBFCF21Q30379686-20A950AB-C76C-463F-8489-4CF020CDD6A7Q31037756-4F0FF5D2-3667-42E8-AEF7-C32CEC218D89Q33291459-7FEE9E51-5929-44C7-8123-9B6F328CCB87Q33383270-1328C4F0-86D7-4533-BBBC-02C500528E82Q33555212-3C35A5C7-3F36-4554-8C9C-7CC9CA3B9044Q33580175-CA915BA8-23E1-430D-87C9-717D0CC54509Q33637053-7BA8DC1D-3A1F-4186-955B-483E8052DAE5Q33639383-EFD2F3D6-D72F-414F-9457-178A18C168D7Q33740717-E59DC205-32B3-4E41-B04C-07096442B6F4Q33916002-BA1F9E58-1A71-4C6E-BEE2-DE69584612CAQ34009449-D1F05168-4359-4326-9323-03926B65306CQ34534982-3C902EDA-D7EB-41C3-ACD6-EC6BA1ED8642Q34572309-D27EFF35-37E3-49BC-B923-81E56AF05D81Q34660799-C169A93B-20DD-43F1-874B-B3446FED524CQ34672506-134E642D-1BC6-4718-96A4-E5679CFC6056Q34729901-311A8CBA-CABE-4D09-99BE-56552F3BB7D7Q34892367-66B80E4F-C1F2-4A4C-9298-98BE495DD7A8Q35184806-0DDD4FA5-0679-4B35-B2EB-42EB96565ED9Q35219246-7743D059-D1D4-42EA-A9A6-D59F27679EB1Q35237644-A1578355-C856-403B-B04E-6061C61B7AE6Q35568516-889A8432-9B50-48CD-9D03-E7D716B53E99Q35880529-8064B7AD-8C5A-4614-BC53-A682B8F1CA9BQ36324336-2F645802-0292-484E-8CB0-E119039EA3C7Q36353298-539304BA-23B3-42E2-9B3C-8D30993E55A5Q36385639-E3A5796D-6B40-4AFD-B89A-D195FB23A6A7Q36564705-726B38AB-39D1-4D56-A9EA-69BB4C0E0BE2Q36573863-64730FCA-B77A-474B-9C5C-A64A8C933446Q36746698-9FBBE508-8A64-4633-AA3E-F96D9BF4B83FQ37066413-CF7182BC-8872-4336-8FCE-E4BEFBFB492AQ37116847-26857BC4-3F55-43E8-BCBC-4E8E7EBB6507Q37260793-F0273903-5134-4A71-B69A-7DDC7E748E53Q37414359-57D8FCD3-F4AC-4A83-A0C6-0522B93C6152Q37519031-B90EF925-0E9C-455D-BAF1-B1662DAD321FQ37584927-9DB8DC61-AC90-426F-81A2-B490F3954322Q37629431-BCB04464-A6E9-49F1-8473-10D8812BD7C5Q37679992-98A16C19-31CA-4CD7-9791-944C41ED2380
P2860
Novel approaches in the therapy of metastatic renal cell carcinoma.
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Novel approaches in the therapy of metastatic renal cell carcinoma.
@ast
Novel approaches in the therapy of metastatic renal cell carcinoma.
@en
Novel approaches in the therapy of metastatic renal cell carcinoma.
@nl
type
label
Novel approaches in the therapy of metastatic renal cell carcinoma.
@ast
Novel approaches in the therapy of metastatic renal cell carcinoma.
@en
Novel approaches in the therapy of metastatic renal cell carcinoma.
@nl
prefLabel
Novel approaches in the therapy of metastatic renal cell carcinoma.
@ast
Novel approaches in the therapy of metastatic renal cell carcinoma.
@en
Novel approaches in the therapy of metastatic renal cell carcinoma.
@nl
P2093
P1476
Novel approaches in the therapy of metastatic renal cell carcinoma
@en
P2093
Arie S Belldegrun
John S Lam
Robert A Figlin
P2888
P304
P356
10.1007/S00345-004-0466-0
P577
2005-04-05T00:00:00Z
P6179
1026746867